Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.44 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.44 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.44 |
| ▸ | PRKDC | P78527 | 1/20 | 0.44 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.43 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3404657 | 0.87 | CYP1A2 (0.50) | CYP1A2CYP2C9ALDH1A1MAPTMAPK1 | |
| SCHEMBL15959211 | 0.85 | CYP1A2 (0.51) | CYP1A2CYP2C9MAPK1POLBPIK3CA | |
| SCHEMBL29728417 | 0.85 | CYP1A2 (0.53) | CYP1A2CYP2C9ALDH1A1MAPTMAPK1 | |
| SCHEMBL3302627 | 0.85 | CYP1A2 (0.53) | CYP1A2CYP2C9ALDH1A1MAPTMAPK1 | |
| SCHEMBL3301348 | 0.83 | CYP1A2 (0.55) | CYP1A2CYP2C9ALDH1A1TRIM24TRIM33 | |
| SCHEMBL2560623 | 0.81 | EPHX2 (0.55) | ALDH1A1KDM4E | |
| SCHEMBL5166171 | 0.81 | CHIA (0.50) | — | |
| SCHEMBL3778169 | 0.80 | CYP1A2 (0.49) | CYP1A2CYP2C9ALDH1A1MAPTMAPK1 | |
| SCHEMBL3778174 | 0.80 | CYP1A2 (0.49) | CYP1A2CYP2C9ALDH1A1MAPTMAPK1 | |
| SCHEMBL31213045 | 0.79 | TRIM24 (0.42) | CYP1A2CYP2C9TRIM24TRIM33LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250186408-A1 | TREATMENT OF PHARMACORESISTANT EPILEPSY | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2025-06-12 | — | — | US | disclosed |
| EP-4333819-A1 | TREATMENT OF PHARMACORESISTANT EPILEPSY | Katholieke Universiteit Leuven (BE) | 2024-03-13 | — | — | EP | disclosed |
| WO-2022233877-A1 | TREATMENT OF PHARMACORESISTANT EPILEPSY | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2022-11-10 | — | — | WO | disclosed |
| CN-109456704-B | Metal Chemical Mechanical Planarization (CMP) compositions and methods thereof | 弗萨姆材料美国有限责任公司 | 2021-08-27 | — | — | CN | disclosed |
| US-10920106-B2 | Metal chemical mechanical planarization (CMP) composition and methods therefore | VERSUM MATERIALS US, LLC (US) | 2021-02-16 | — | — | US | disclosed |
| US-20200032107-A1 | Metal Chemical Mechanical Planarization (CMP) Composition And Methods Therefore | VERSUM MATERIALS US, LLC (US) | 2020-01-30 | — | — | US | disclosed |
| US-10465096-B2 | Metal chemical mechanical planarization (CMP) composition and methods therefore | VERSUM MATERIALS US, LLC (US) | 2019-11-05 | — | — | US | disclosed |
| US-20190263800-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | PLEXXIKON INC. | 2019-08-29 | — | — | US | disclosed |
| US-20170247370-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | PLEXXIKON INC. | 2017-08-31 | — | — | US | disclosed |
| US-20170247370-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | PLEXXIKON INC. | 2017-08-31 | — | — | US | disclosed |
| US-20080312234-A1 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | AMOREPACIFIC CORPORATION (KR) | 2008-12-18 | — | — | US | disclosed |
| CN-101123959-A | Aryl, heteroaryl and bicyclic aryl nitrone compounds, prodrugs and pharmaceutical compositions thereof for the treatment of human diseases | RENOVIS INC (US) | 2008-02-13 | — | — | CN | disclosed |
| WO-2008013414-A1 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | AMOREPACIFIC CORPORATION (KR) | 2008-01-31 | — | — | WO | disclosed |
| US-20070275932-A1 | Aryl, heteroaromatic and bicyclic aryl nitrone compounds, prodrugs and pharmaceutical compositions of the same to treat human disorders | RENOVIS, INC. | 2007-11-29 | — | — | US | disclosed |
| US-20070161643-A1 | Pyridin-2-one compounds useful as inhibitors of thrombin | ASTRAZENECA AB (SE) | 2007-07-12 | — | — | US | disclosed |
| EP-1713774-A1 | NEW PYRIDIN-2-ONE COMPOUNDS USEFUL AS INHIBITORS OF THROMBIN | AstraZeneca AB (SE) | 2006-10-25 | — | — | EP | disclosed |
| EP-1660011-A2 | ARYL, HETEROAROMATIC AND BICYCLIC ARYL NITRONE COMPOUNDS, PRODRUGS AND PHARMACEUTICAL COMPOSITIONS OF THE SAME TO TREAT HUMAN DISORDERS | Renovis, Inc. (US) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005075424-A1 | NEW PYRIDIN-2-ONE COMPOUNDS USEFUL AS INHIBITORS OF THROMBIN | ASTRAZENECA AB (SE) | 2005-08-18 | — | — | WO | disclosed |
| US-20050059638-A1 | Aryl, heteroaromatic and bicyclic aryl nitrone compounds, prodrugs and pharmaceutical compositions of the same to treat human disorders | RENOVIS, INC. | 2005-03-17 | — | — | US | disclosed |
| WO-2005016272-A2 | ARYL, HETEROAROMATIC AND BICYCLIC ARYL NITRONE COMPOUNDS, PRODRUGS AND PHARMACEUTICAL COMPOSITIONS OF THE SAME TO TREAT HUMAN DISORDERS | RENOVIS, INC. (US) | 2005-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275932-A1 | Aryl, heteroaromatic and bicyclic aryl nitrone compounds, prodrugs and pharmaceutical compositions of the same to treat human disorders | AHR, NAT1, ARNT | CYP1A2 19/4885CYP2C9 35/4885ALDH1A1 487/4885 |
| US-20080312234-A1 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | TRPV1, TRPA1, TRPV2 | CYP1A2 1436/4885CYP2C9 835/4885ALDH1A1 797/4885 |
| US-20170247370-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | KIT, FLT3, FLT1 | CYP1A2 4297/4885CYP2C9 4122/4885ALDH1A1 1818/4885 |
| US-20250186408-A1 | TREATMENT OF PHARMACORESISTANT EPILEPSY | CNR1, CNR2, CYP2J2 | CYP1A2 14/4885CYP2C9 113/4885ALDH1A1 1412/4885 |
| US-20050059638-A1 | Aryl, heteroaromatic and bicyclic aryl nitrone compounds, prodrugs and pharmaceutical compositions of the same to treat human disorders | AHR, NAT1, ARNT | CYP1A2 19/4885CYP2C9 35/4885ALDH1A1 487/4885 |
| US-20070161643-A1 | Pyridin-2-one compounds useful as inhibitors of thrombin | PLG, F2, PLAT | CYP1A2 165/4885CYP2C9 217/4885ALDH1A1 1813/4885 |
| US-20190263800-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | KIT, FLT3, FLT1 | CYP1A2 4345/4885CYP2C9 4093/4885ALDH1A1 1879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.